Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on the stock. StockNews.com lowered shares of Horizon Therapeutics Public from a "buy" rating to a "hold" rating in a report on Friday. Morgan Stanley decreased their target price on Horizon Therapeutics Public from $135.00 to $90.00 and set an "overweight" rating on the stock in a report on Thursday. Oppenheimer restated a "buy" rating and issued a $140.00 price objective on shares of Horizon Therapeutics Public in a research report on Friday, July 8th. The Goldman Sachs Group dropped their price target on Horizon Therapeutics Public from $164.00 to $144.00 and set a "buy" rating for the company in a research note on Thursday. Finally, BMO Capital Markets lowered their price objective on Horizon Therapeutics Public from $145.00 to $117.00 and set an "outperform" rating for the company in a research note on Thursday. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $117.22.
Horizon Therapeutics Public Price Performance
Shares of HZNP Stock opened at $69.60 on Monday. The stock has a 50 day moving average price of $83.03 and a 200 day moving average price of $93.43. The firm has a market capitalization of $16.00 billion, a P/E ratio of 21.48, a P/E/G ratio of 1.46 and a beta of 1.12. Horizon Therapeutics Public has a 52-week low of $60.76 and a 52-week high of $120.54. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.79 and a current ratio of 4.05.
Horizon Therapeutics Public (NASDAQ:HZNP - Get Rating) last released its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported $1.07 EPS for the quarter, missing the consensus estimate of $1.36 by ($0.29). The firm had revenue of $876.40 million for the quarter, compared to analysts' expectations of $938.82 million. Horizon Therapeutics Public had a return on equity of 27.90% and a net margin of 20.06%. The company's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.62 earnings per share. As a group, sell-side analysts predict that Horizon Therapeutics Public will post 5.08 earnings per share for the current year.
Insiders Place Their Bets
In other news, EVP Andy Pasternak sold 762 shares of Horizon Therapeutics Public stock in a transaction on Friday, June 10th. The stock was sold at an average price of $85.36, for a total value of $65,044.32. Following the transaction, the executive vice president now directly owns 38,897 shares in the company, valued at approximately $3,320,247.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, EVP Andy Pasternak sold 762 shares of Horizon Therapeutics Public stock in a transaction on Friday, June 10th. The stock was sold at an average price of $85.36, for a total value of $65,044.32. Following the transaction, the executive vice president now directly owns 38,897 shares in the company, valued at approximately $3,320,247.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Timothy P. Walbert sold 25,000 shares of Horizon Therapeutics Public stock in a transaction on Friday, May 20th. The shares were sold at an average price of $90.00, for a total value of $2,250,000.00. Following the completion of the transaction, the chief executive officer now owns 460,549 shares in the company, valued at $41,449,410. The disclosure for this sale can be found here. Insiders have sold 98,384 shares of company stock worth $8,934,633 in the last ninety days. 2.50% of the stock is owned by company insiders.
